Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Rebecsinib, a Spliceosome Modulator That Inhibits ADAR1, in Patients With Relapsed or Refractory Secondary Acute Myeloid Leukemia or Higher-Risk Myelofibrosis

NCT07250646 is registered in ClinicalTrials.gov with Aspera Biomedicines, Inc. as lead sponsor.

NCT NCT07250646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07250646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Rebecsinib, a Spliceosome Modulator That Inhibits ADAR1, in Patients With Relapsed or Refractory Secondary Acute Myeloid Leukemia or Higher-Risk Myelofibrosis
Lead sponsor
Aspera Biomedicines, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
May 21, 2026
Completion date
April 30, 2028
Enrollment
28 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis, secondary aml